Insider trade

Cencora (COR): Officer received 3,936 units

Lazarus Krikorian, Officer at Cencora, reported a grant / award of 3,936 units.

3,936
Derivative units
Traded
Apr 1, 2026
Filed
Apr 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 2, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  2. Feb 2, 2026Federal contract · $4.3M obligatedDepartment of Defense awarded Cencora: $4.34M obligated to date
  3. Feb 3, 2026Federal contract · $4.9M obligatedDepartment of Defense awarded Cencora: $4.93M obligated to date
  4. Feb 13, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  5. Feb 18, 2026Federal contract · $5.2M obligatedDepartment of Defense awarded Cencora: $5.18M obligated to date
  6. Feb 18, 2026Federal contract · $4.8M obligatedDepartment of Defense awarded Cencora: $4.79M obligated to date
  7. Feb 18, 2026InsiderCEO sold ~$479K of COR shares in the open market
  8. Feb 20, 2026InsiderCEO sold ~$1.35M of COR shares in the open market
  9. Mar 11, 2026Federal contract · $9.0M obligatedDepartment of Defense awarded Cencora: $9.01M obligated to date
  10. Mar 16, 2026FDARecall: Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Distributed…
  11. Mar 17, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 17, 2026, Cencora, Inc. (the “Company”) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026.”
  12. Mar 23, 2026Congress · 1 personMembers of Congress: 2 purchases
  13. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  14. Mar 27, 2026CongressDisclosed purchase of COR — reported range $1,001 - $15,000
  15. Mar 31, 2026CongressDisclosed purchase of COR — reported range $1,001 - $15,000

What came next

  1. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.3%
  2. May 1, 2026FDARecall: Primidone Tablets, USP, 50 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217. Ca…
  3. May 1, 2026FDARecall: Primidone Tablets, USP, 250 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217. C…
  4. May 6, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  5. May 6, 2026Congress · 1 personMembers of Congress: 2 sales
  6. May 13, 2026Federal contract · $4.5M obligatedDepartment of Defense awarded Cencora: $4.5M obligated to date
  7. May 13, 2026Federal contract · $4.3M obligatedDepartment of Defense awarded Cencora: $4.25M obligated to date
  8. May 23, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 27, 2026, Cencora, Inc. (the “Company”) announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company (the “Appointment”), effective June 29, 2026 (the “Effective Date”).”
  9. May 28, 2026Insider · Largest insider buy since 2006Director purchased ~$1.07M of COR shares in the open market
  10. Jun 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 15, 2026, Cencora, Inc. (the “Company”) announced that Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of the Company effective July 12, 2026.”
  11. Jun 12, 2026Federal contract · $7.7M obligatedDepartment of Defense awarded Cencora: $7.74M obligated to date
  12. Jun 18, 2026InsiderDirector purchased ~$1.1M of COR shares in the open market
  13. Jun 22, 2026Insider · Their first buy on recordDirector purchased ~$149K of COR shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cencora

For Cencora, OQRO holds 8 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COR page.

Other recent filings by Lazarus Krikorian, SVP & Chief Accounting Officer

The full history of Lazarus Krikorian, SVP & Chief Accounting Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Cencora (COR) insider traded, and how much?

Lazarus Krikorian, Officer at Cencora, reported a grant / award of 3,936 units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Apr 1, 2026. Filed: Apr 3, 2026. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Cencora recently?

For Cencora, OQRO holds 8 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the COR page.

Does this mean COR stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Cencora

Everything OQRO holds on this company is on its COR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data